³í¹®) Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multiinstitutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14) ¿¬¼¼¾Ïº´¿ø Á¾¾ç³»°ú ÃÖÇýÁø, ÀÌÃæ±Ù ±³¼ö ¿¬±¸ÆÀ